Medical/Pharmaceuticals
Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform Announced - World Premiere
SHANGHAI, June 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals officially
launched STAL (Super-Trillion Antibody Libraries) onJune 3, 2022, which is a
super-trillion innovative antibody drug discovery platform of Sanyou's own
intellectual property.
2022-06-03 08:00
3159
Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer
SHANGHAI and SAN DIEGO, June 2, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced the appointment ofXiaoning Guo, Ph.D., as the Chief Medical Officer (CMO). Dr. Xiaoning Guo will have overall responsibility for the drug development functio...
2022-06-02 21:00
3321
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more efficient drug development WOODINVILLE, Wash. and SUZHOU, China...
2022-06-02 20:00
3309
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia, June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...
2022-06-02 20:00
3403
Winner Medical Acquires Majority Stake in Pingan Medical to Fuel Growth
SHENZHEN, China, June 1, 2022 /PRNewswire/ -- Winner Medical Co. Ltd. (300888.SZ; "Winner Medical" and "the Company"), a leading manufacturerof disposable wound care and surgical products, announced onMay 18 that it will acquire a majority 65.55% stake in Hunan Pingan Medical Device Technology Co...
2022-06-02 11:08
2710
Concord Medical Announces Its Subsidiary's Application Filing for Potential Listing on The Stock Exchange of Hong Kong Limited
BEIJING, June 1, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensiv...
2022-06-02 04:15
2975
First AI to Refine Medical Coding by Exploring Therapeutic Data
SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Medical AI start-up Aesop
Technology announced a new partnership that made their new product,DxPrime
2022-06-02 01:22
3703
Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the progress ...
2022-06-01 21:24
3318
Standigm Signs MOU with Merck Korea for AI drug Discovery Research
- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...
2022-06-01 21:00
3093
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
SHANGHAI, June 1, 2022 /PRNewswire/ -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxu...
2022-06-01 19:49
2567
Avulux and CR Surfacing partner to make innovative migraine & light sensitivity lenses available through eye-care practitioners across Australia
Australians living with migraine can now come 'out of the dark' with Avulux migraine lenses DANDENONG SOUTH, Australia, June 1, 2022 /PRNewswire/ -- The world's first clinically proven lens for migraine and light sensitivity management is now available through eye-care practitioners inAustralia....
2022-06-01 05:00
3095
Toku Eyes, Developer of an AI Platform That Accurately Identifies Risk of Heart Attack Using an Eye Image, Expands to The US
With Toku Eyes' artificial intelligence platform, the eye is not only the window to the soul — it is now a window to the state of your health AUCKLAND, New Zealand, May 31, 2022 /PRNewswire/ -- Toku Eyes, the New Zealand -based developer of a multi-modal artificial intelligence platform for instan...
2022-06-01 00:00
2860
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...
2022-05-31 22:30
4168
Volition Achieves CE Mark for Nu.Q® NETs Test
to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluat...
2022-05-31 20:00
4070
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...
2022-05-31 20:00
2253
GBM AGILE OPENS TO PAXALISIB IN EUROPE
SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm inEurope. University Hospital Zurich...
2022-05-31 19:20
4495
Illuccix® Granted Transitional Pass-Through Payment Status
INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...
2022-05-31 19:00
2013
Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO
SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...
2022-05-31 17:56
1237
AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...
2022-05-31 11:30
1980
Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists
Preclinical Studies on the Potential Application of Transcenta's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage bio...
2022-05-31 08:08
1987
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 320 media titles]
2026-08-28 09:01Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36